肠道菌群在肝性脑病中的作用机制

姬晓彤; 贺韵涵; 戚莹媛; 杨晓航

doi:10.3969/j.issn.1001-5256.2020.03.049

肠道菌群在肝性脑病中的作用机制

DOI: 10.3969/j.issn.1001-5256.2020.03.049

陕西中医药大学医学技术学院

详细信息

中图分类号: R575.3
计量
- 文章访问数: 892
- HTML全文浏览量: 13
- PDF下载量: 215
- 被引次数: 0
出版历程
- 收稿日期: 2019-09-03
- 出版日期: 2020-03-20

Mechanism of action of intestinal flora in hepatic encephalopathy

School of Medical technology,Shaanxi University of Chinese Medicine

摘要

摘要: 肝性脑病临床症状多样,病因及发病机制目前尚未完全清楚,近年来研究发现肠道菌群组成与肝性脑病患者的中枢神经系统改变有关。在近年来国内外相关研究的基础上,从微生物学、神经系统及免疫学的角度分析并总结了肠道菌群通过肝-脑轴对肝性脑病的调控机制,认为深入研究肠道菌群的作用机制对肝性脑病的治疗很有必要,可为临床提供更明确的诊疗依据。
- 肝性脑病 /
- 肠道菌群-肝-脑轴 /
- 免疫系统 /
- 菌群移植
Abstract: Hepatic encephalopathy( HE) has various clinical symptoms,and its etiology and pathogenesis have not been fully understood.Recent studies have shown that the composition of intestinal flora is associated with the changes in the central nervous system in patients with HE. With reference to recent studies in China and foreign countries,this article analyzes and summarizes the regulatory mechanism of intestinal flora on HE through the liver-brain axis from the perspectives of microbiology,nervous system,and immunology,and it is pointed out that in-depth studies on the mechanism of action of intestinal flora are needed for the treatment of HE and can provide a clear basis for clinical diagnosis and treatment.
- hepatic encephalopathy /
- microecology-gut-brain axis /
- immune system /
- flora transplantation

HTML全文

参考文献(34)

[1] American Association for the Study of Liver Diseases,European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease:2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases[J]. J Hepatol,2014,61(3):642-659.

[2] TANG SH,CHEN H,HAN GH. Association between gut microbiota and hepatic encephalopathy in patients with liver cirrhosis[J]. J Clin Hepatol,2019,35(5):1109-1113.(in Chinese)汤世豪，陈辉，韩国宏．肠道菌群与肝硬化肝性脑病的关系[J]．临床肝胆病杂志，2019,35(5):1109-1113.

[3] LU BJ,ZHAO YH,AN YT,et al. Research advances in gut microbiota in liver cirrhosis and related complications[J]. J Clin Hepatol,2018,34(11):2433-2437.(in Chinese)鲁冰洁，赵亚红，安泳潼，等．肠道微生物在肝硬化及相关并发症中的研究进展[J]．临床肝胆病杂志，2018,34(11):2433-2437.

[4] SENGHOR B,SOKHNA C,RUIMY R,et al. Gut microbiota diversity according to dietary habits and geographical provenance[J]. Hum Microbiome J,2018,7-8:1-9.

[5] DAVID L,MAURICE CF,CARMODY RN,et al. Diet rapidly and reproducibly alters the human gut microbiome[J]. Nature,2014,505(7484):559-563.

[6] GRAF D,di CAGNO R,FK F,et al. Contribution of diet to the composition of the human gut microbiota[J]. Microb Ecol Health Dis,2015,26:26164.

[7] MOGHADAMRAD S,MCCOY KD,GEUKING MB,et al. Attenuated portal hypertension in germ-free mice:Function of bacterial flora on the development of mesenteric lymphatic and blood vessels[J]. Hepatology,2015,61(5):1685-1695.

[8] TABIBIAN J,O'HARA SP,TRUSSONI CE,et al. Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis[J]. Hepatology,2016,63(1):185-196.

[9] CHU H,DUAN Y,YANG L,et al. Small metabolites,possible big changes:A microbiota-centered view of non-alcoholic fatty liver disease[J]. Gut,2019,68(2):359-370.

[10] HE X,JI G,JIA W,et al. Gut microbiota and nonalcoholic fatty liver disease:Insights on mechanism and application of metabolomics[J]. Int J Mol Sci,2016,17(3):300.

[11] LYU XY,LI L. Clinical effect of rifaximin in treatment of complications associated with liver cirrhosis[J]. J Clin Hepatol,2018,34(7):1551-1554.(in Chinese)吕新月，李磊．利福昔明在肝硬化相关并发症中的应用[J]．临床肝胆病杂志，2018,34(7):1551-1554

[12] ZHU X,HAN Y,DU J,et al. Microbiota-gut-brain axis and the central nervous system[J]. Oncotarget,2017,8(32),53829-53838.

[13] SHARON G,SAMPSON TR,GESCHWIND DH,et al. The central nervous system and the gut microbiome[J]. Cell,2016,167(4):915-932.

[14] ARONIADIS OC,DROSSMAN DA,SIMRÉN M. Perspective on brain-gut communication:The American Gastroenterology Association and American Psychosomatic Society joint symposium on brain-gut interactions and the intestinal microenvironment[J]. Psychosom Med,2017,79(8):847-856.

[15] LYTE JM,PROCTOR A,PHILLIPS GJ,et al. Altered schaedler flora mice:An old defined microbiota animal model to study the new science of microbiota-gut-brain axis[J]. Behav Brain Res,2019,356:221-226.

[16] AHLUWALIA V,BETRAPALLY NS,HYLEMON PB,et al. Impaired gut-liver-brain axis in patients with cirrhosis[J]. Sci Rep,2016,6:26800

[17] QIN N,YANG F,LI A,et al. Alterations of the human gut microbiome in liver cirrhosis[J]. Nature,2014,513(7516):59-64.

[18] FUKUI H. Gut Microbiome-based Therapeutics in liver cirrhosis:basic consideration for the next step[J]. J Clin Transl Hepatol,2017,5(3):249-260.

[19] LACHAR J,BAJAJ JS. Changes in the microbiome in cirrhosis and relationship to complications:Hepatic encephalopathy,spontaneous bacterial peritonitis,and sepsis[J]. Semin Liver Dis,2016,36(4):327-330.

[20] WEISS N,BARBIER SAINT HILAIRE P,COLSCH B,et al. Cerebrospinal fluid metabolomics highlights dysregulation of energy metabolism in overt hepatic encephalopathy[J]. J Hepatol,2016,65(6):1120-1130.

[21] BENYOUB K,MULLER M,BONNET A,et al. Amounts of bile acids and bilirubin removed during single-pass albumin dialysis in patients with liver failure[J]. Ther Apher Dial,2011,15(5):504-506.

[22] TANAKA N,MATSUBARA T,KRAUSZ KW,et al. Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis[J]. Hepatology,2012,56(1):118-129.

[23] COLPITTS SL,KASPER LH. Influence of the gut microbiome on autoimmunity in the central nervous system[J]. J Immunol,2017,198(2):596-604.

[24] ARAB JP,MARTIN-MATEOS RM,SHAH VH,et al. Gut–liver axis,cirrhosis and portal hypertension:The chicken and the egg[J]. Hepatol Int,2018,12(Suppl 1):24-33.

[25] DAPITO DH,MENCIN A,GWAK GY,et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4[J]. Cancer Cell,2012,21(4):504-516.

[26] BAJAJ JS,BETRAPALLY NS,GILLEVET PM. Decompensated cirrhosis and microbiome interpretation[J]. Nature,2015,525(7569):e1-e2.

[27] DANTZER R. Neuroimmune interactions:From the brain to the immune system and vice versa[J] Physiol R,2018,98(1):477-504.

[28] ERHARDT S,SCHWIELER L,IMBEAULT S,et al. The kynurenine pathway in schizophrenia and bipolar disorder[J]. Neuropharmacology,2017,112(Pt B):297-306.

[29] LUO X,LUO S,ZHENG YY. Intestinal dysbacteriosis promotes intestinal intraepithelial T lymphocyte activation and proinflammatory cytokine secretion in mice[J]. Chin J Cell Mol Immunol,2016,32(8):1031-1035.(in Chinese)罗霞，罗爽，郑彦懿．肠道菌群失调增加肠上皮T淋巴细胞活化和促炎细胞因子分泌[J]．细胞与分子免疫学杂志，2016,32(8):1031-1035.

[30] QUAN M,XING HC. Research progress on intestinal flora and chronic liver disease[J/CD]. Chin J Liver Dis(Electronic Edition),2019,11(3):26-30.(in Chinese)全敏，邢卉春．肠道菌群与慢性肝病相关研究进展[J/CD]．中国肝脏病杂志(电子版)，2019,11(3):26-30.

[31] HOFFMANN D,PALUMBO F,RAVEL J,et al. Improving regulation of microbiota transplants[J]. Science,2017,358(6369):1390-1391.

[32] SARIN SK,PANDE A,SCHNABL B. Microbiome as therapeutic target in alcohol-related liver disease[J]. J Hepatol,2019,70(2):260-272.

[33] BAJA JS,KASSAM Z,FAGAN A,et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy:A randomized clinical trial[J]. Hepatology,2017,66(6):1727-1738.

[34] PHILIPS CA,PANDE A,SHASTTHRY SM,et al. Healthy donor fecal microbiota transplantation in steroidineligible severe alcoholic hepatitis:A pilot study[J]. Clin Gastroenterol Hepatol,2017,15(4):600-602.

施引文献

资源附件(0)

访问统计